Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2015)
Jazz Pharmaceuticals (JAZZ) recorded quarterly Income from Non-Controlling Interests of -$1000.0 in Q2 2015, little changed quarter-over-quarter from -$1000.0 in Q4 2014, and up 98.63% on a YoY basis from -$503.45 in Q2 2014.
Jazz Pharmaceuticals (JAZZ) Income from Non-Controlling Interests (2014 - 2015) Analysis & Trends
Jazz Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$1000.0 for Q2 2015.
- In Q2 2015, Income from Non-Controlling Interests rose 98.63% year-over-year to -$1000.0; the TTM figure through Jun 2016 stood at -$1000.0 (changed N/A YoY), while the FY2015 annual figure was -$1000.0, up 99.91% from the prior year.
- Income from Non-Controlling Interests was -$1000.0 for Q2 2015 at Jazz Pharmaceuticals, roughly flat from -$1000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $2000.0 in Q3 2014 to a low of -$989000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 13.91 Bn | 12.06 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | -1,000.00 |
| Dec 31, 2014 | -1,000.00 |
| Sep 30, 2014 | 2,000.00 |
| Jun 30, 2014 | -73,000.00 |
| Mar 31, 2014 | -989,000.00 |